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Oxidative stress has been reported to induce cognitive impairment in Parkinson’s disease. This paper aimed to determine the eﬀect
of quercetin, a substance possessing antioxidant activity, on the cognitive function in a rat model of Parkinson’s disease. Male
Wistar rats, weighing 200–250g, were orally given quercetin at doses of 100, 200, 300mg/kg BW once daily for a period of 14 days
before and 14 days after the unilateral lesion of right substantia nigra induced by 6-hydroxydopamine (6-OHDA). Their spatial
memorywasassessedat7and14daysoftreatmentandneurondensitywasdetermined,malondialdehyde(MDA)level,theactivity
of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) were evaluated at the end of the experiment. In
addition, the activity of acetylcholinesterase (AChE) was also measured. It was found that all doses of quercetin enhanced spatial
memory. Therefore, it is suggested that the cognitive-enhancing eﬀect of quercetin occurs partly because of decreased oxidative
damage resulting in increased neuron density.
1.Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disease. To date, the precise mechanism
responsible for pathogenesis of PD is not well understood.
Accumulating lines of evidence have demonstrated that
oxidative stress plays a crucial role on the pathogenesis of
PD[1–5].Themotorimpairmentobservedinpatientsseems
to be the most notable point of concern when prescribing
medicine or planning treatment. In recent years, it was
indicated that nonmotor deﬁcits became an important part
of patient management [6]. It has been known that patients
intheearlystagesofPDalreadyhaveimpairmentofcognitive
performance and this deﬁcit in turn gives rise to a poor
qualityoflife[7,8]andeconomicburden[9].Recently,itwas
found that 6-hydroxydopamine (6-OHDA) was recognized
a sag o o dm o d e lf o re a r l ys t a g e so fP D ,e s p e c i a l l yi n
terms of emotional and cognitive deﬁcits [10]. Although the
substantia nigra is the brain area that has been indicated
to be the most vulnerable to neurodegeneration in PD and
mediates the clinical manifestation (rigidity, resting tremor,
slowness of voluntary movement, and postural instability),
but other brain regions such as locus ceruleous, raphe
neuclei, nucleus basalis of Meynert, and the brain area that
responsible for cognition, hippocampus, were also aﬀected.
Previous MRI studies clearly revealed that decreased hip-
pocampal volume accompanied the cognitive impairment
in PD patients [11–13]. Based on the role of oxidative
stress on the pathophysiology of PD, the neuroprotective
and cognitive enhancing eﬀects of substances possessing
antioxidant activity have gained much attention.
Quercetin (QC) is a polyphenolic compound found in
common vegetables and fruits such as onions, broccoli, and
apples. Previous studies have demonstrated that quercetin2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀect of quercetin on escape latency in the Morris water
maze test in an animal model of Parkinson’s disease induced by 6-
OHDA. Data were expressed as mean ± S.E.M. for 8 rats in each
group. ∗∗∗P < 0.001 compared to control; #P < 0.05; ##P < 0.01;
###P < 0.001 compared to the vehicle + 6-OHDA-treated group.
contains many good biological properties for human health
including antioxidant [14], anti-inﬂammation [15], and
anticancer [16] activities. Recently, it has been reported
that quercetin can pass through the blood-brain barrier
of in situ models [17]. In addition, quercetin exerts the
protectiveeﬀectinastrokemodelinducedbytransientglobal
ischemia[18].Quercetinsigniﬁcantlyprotectedtheneuronal
cells from the oxidative stress-induced neurodegeneration
in Alzheimer’s disease [19], decreased lipid peroxidation,
improved the activity of catalase and superoxide dismutase
[20] and also prevented glutathione depletion [21]. Previous
study showed that the EGb761, a standardized extract from
the herbal medicine Ginkgo biloba, contains a high amount
of quercetin and exhibits the neuroprotective eﬀect against
oxidativedamageinducedby6-OHDA[22].Moreover,itwas
found that quercetin attenuated the neuronal death in the
hippocampus resulting in improved learning and memory in
arm maze test [23]. Therefore, these pieces of evidence point
out the possibility that quercetin might exert an inﬂuence on
the central nervous system.
Based on the antioxidant and anti-inﬂammatory actions
of QC, we hypothesized that QC might mitigate the neu-
rotoxicity and cognitive impairment in an animal model
of PD induced by 6-OHDA. To elucidate this issue, the
current study aimed to determine the eﬀects of QC on
spatial memory and neuron density in the hippocampus of
an animal model of PD induced by 6-OHDA. In addition,
the possible underlying mechanism was also investigated.
2.MaterialsandMethods
2.1. Animals. A d u l tm a l eW i s t a rr a t s( 1 0w e e k so l d )w e r e
obtained from the National Laboratory Animal Center,
Salaya, Nakhon Pathom. The animals weighted between 200
to 250grams at the beginning of experiment. They were
housed 5 per cage and maintained in 12:12 light:dark cycle
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Figure 2: Eﬀect of quercetin on retention time in the Morris water
maze test in an animal model of Parkinson’s disease induced by 6-
OHDA. Data were expressed as mean ± S.E.M. for 8 rats in each
group. ∗P < 0.05; ∗∗P < 0.01 compared to control; #P < 0.05; ##P <
0.01 compared to the vehicle + 6-OHDA-treated group.
and given access to food and water ad libitum.T h ee x p e r -
iments were performed to minimize animal suﬀering in
accordance with the internationally accepted principles for
laboratory use and care of European Community (EEC
directive of 1986; 86/609/EEC). The experimental protocols
were approved by the Institutional Animal Care and Use
Committee.
2.2. Drugs and Chemicals. Quercetin was purchased from
Sigma-Aldridge Company. All chemical substances used in
this study were analytical grade. Both Levodopa (L-dopa),
a standard drug used for PD treatment, and vitamin C,
an antioxidant possessing the neuroprotective and cognitive
enhancingeﬀects,wereusedaspositivecontrolsinthisstudy.
Normalsalinesolution(NSS)wasusedasvehiclethroughout
the study. All administered substances were freshly prepared.
2.3. Experimental Protocol. T h ea n i m a l sw e r er a n d o m l y
divided into 7 groups (n = 8 animals/group) as described
below.
Group I: Control. Animals were not treated with any
drugs or injections.
Group II: Vehicle plus 6-OHDA injection. Animals were
treated with NSS once daily via oral route for 14 days before
and 14 days after the injection of 6-OHDA into the right
substantia nigra.
Groups III–V: Rats were treated with quercetin at various
doses ranging from 100, 200, and 300mg/kg BW once daily
via oral route for 14 days before and 14 days after the
injection of 6-OHDA into the right substantia nigra.
Groups VI–VII: Rats were orally treated with either
Levodopa (L-dopa; 5mg/kg BW) or vitamin C (200mg/kg)
once daily for 14 days before and 14 days after the lesion of
the right substantia nigra induced by 6-OHDA.
Each rat in all groups, except the control group, was
orally given the same volume of substance suspension for
14 days. The rats were then subjected to 6-OHDA injectionEvidence-Based Complementary and Alternative Medicine 3
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Figure 3: Eﬀect of quercetin on neuron density in various subregions of the hippocampus (a = CA1; b = CA2; c = CA3; d = Dentate gyrus)
in an animal model of Parkinson’s disease induced by 6-OHDA. Scale bars 50µm, the magniﬁcation was 40X. Data were expressed as mean
± S.E.M. for 8 rats in each group. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared to control; #P < 0.05; ##P < 0.01 compared to the vehicle +
6-OHDA-treated group.4 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of quercetin on the activity of acetylcholinesterase
(AChE) in the hippocampus in an animal model of Parkinson’s
diseaseinducedby6-OHDA.Datawereexpressedasmean ±S.E.M.
for 8 rats in each group. #P < 0.05 compared to the vehicle + 6-
OHDA-treated group.
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Figure 5: Eﬀect of quercetin on the level of malondialdehyde
(MDA) in the hippocampus in an animal model of Parkinson’s
diseaseinducedby6-OHDA.Datawereexpressedasmean ±S.E.M.
for 8 rats in each group.∗∗P < 0.01 compared to control; #P < 0.05
compared to the vehicle + 6-OHDA-treated group.
using the stereotaxic apparatus. The 6-OHDA infusion was
performed using a Hamilton syringe and rats were allowed
to recover after the lesion for 6 days. They were then tested
for spatial memory using Morris water maze test at 7 and 14
days after 6-OHDA injection. At the end of experiment, rats
weresacriﬁcedandtheirbrainswereremovedandthedensity
of survival neurons, the activity of acetylcholinesterase
(AChE), and scavenger enzymes including superoxide dis-
mutase (SOD), catalase (CAT), and glutathione peroxidase
(GPx) in the hippocampus were determined. Moreover, the
malondialdehyde (MDA) level in the mentioned area was
also determined.
2.4. The Administration of 6-OHDA. 6-OHDA was prepared
as described previously by Ferro and coworkers [24]. Rats
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Figure 6:Eﬀectofquercetinontheactivityofsuperoxidedismutase
(SOD) in the hippocampus in an animal model of Parkinson’s
diseaseinducedby6-OHDA.Datawereexpressedasmean ±S.E.M.
for 8 rats in each group. ##P < 0.01 compared to the vehicle + 6-
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Figure 7: Eﬀect of quercetin on the activity of glutathione
peroxidase (GPx) in the hippocampus in an animal model of
Parkinson’s disease induced by 6-OHDA. Data were expressed as
mean ± S.E.M. for 8 rats in each group. ∗∗P < 0.01 compared to
control; #P < 0.05; ##P < 0.01; compared to the vehicle + 6-OHDA-
treated group.
were anesthetized with 50mg/kg sodium thiopental (i.p.),
each animal was mounted on a stereotaxic stand, the skin
overlying the skull was cut to expose the skull, and the
coordinates for the substantia nigra par compacta (SNpc)
were accurately measured (anteroposterior −0.5mm from
bregma, mediolateral 2.1mm from midline, and dorsoven-
tral −7.7mm from the skull). The 6µg of 6-OHDA, which
dissolved in 2µL 0.2% ascorbic acid saline, were perfused
into SNpc through a 30-gauge stainless needle. After the
surgery, animals were allowed to recover from anesthesia and
then placed in their cages.
2.5. Morris Water Maze Test. The water maze consisted of
a metal pool (170cm in diameter × 58cm tall) ﬁlled with
tap water (25◦C, 40cm deep). The pool was divided intoEvidence-Based Complementary and Alternative Medicine 5
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Figure 9: Hypothetical diagram of the possible underlying mech-
anism for the cognitive enhancing eﬀect of quercetin on an animal
model of Parkinson’s disease induced by 6-OHDA.
4 quadrants (NE, NW, SE, and SW) by two imaginary
lines crossing the center of the pool. The water surface was
covered with nontoxic milk. The removable platform was
placed below the water level at the center of one quadrant.
For each animal, the location of the invisible platform was
placed at the center of one quadrant and remained there
throughout training. The rats must memorize the platform
location in relation to various environmental cues because
the location of the escape platform in and outside the pool
is not visible. Each rat was gently placed in the water facing
the wall of the pool from one of the four starting points
(N, E, S, or W) along the perimeter of the pool, and the
animal was allowed to swim until it found and climbed
onto the platform. During training session, the rat was
gently placed on the platform when it could not reach the
platform in 60 seconds. In either case, the subject was left on
theplatformfor15secondsandthenremovedfromthepool.
The time for animals to climb on the hidden platform was
recorded as escape latency or acquisition time. In order to
determine the capability of the animals to retrieve and retain
information, the platform was removed 24hr later and the
ratwasreleased into the quadrantdiagonallyopposite to that
which contained the platform. Time spent in the region that
previously contained the platform was recorded as retention
time. In each trial, the animal was quickly dried with towel
before being returned to the cage [25].
2.6. Histological Procedure. Following anesthesia with
sodium pentobarbital (50mg/kg BW), the brain ﬁxation was
carried out by transcardial perfusion with a ﬁxative solution
containing 4% paraformaldehyde in 0.1M phosphate buﬀer
pH 7.3. After the perfusion, the brains were removed and
stored overnight in a ﬁxative solution that is used for per-
fusion. They were then inﬁltrated with 30% sucrose solution
at, and kept at, 4◦C. The specimens were frozen rapidly and
the coronal sections at 30µM thick were prepared using
cryostat. All sections were rinsed in the phosphate buﬀer
and picked up on slides coated with 0.01% aqueous solution
of a high molecular weight poly L-lysine.
2.7. Nissl Staining. The duplicate coronal sections of brains
were stained with 0.75% cresyl violet, dehydrated through
graded alcohols (70, 95, 100% 2x), placed in xylene, and
mounted using DPX.
2.8. Determination of Acetylcholinesterase, Superoxide Dismu-
tase, Glutathione Peroxidase and Catalase Activity, and the
Malondialdehyde Level. The rats were divided into various
groups as previously described in the experimental protocol.
After the last dose of administration, all rats were sacriﬁced.
The hippocampus of the lesion side was isolated and
prepared as a homogenate to determine the MDA level and
the activities of AChE, SOD, CAT, and GPx. MDA was
estimatedbydeterminingtheaccumulationofthiobarbituric
acid reactive substances (TBARS) [26] in the hippocampal
homogenate whereas the activities of acetylcholinesterase
[27], superoxide dismutase [28], glutathione peroxides [29],
and catalase [30] were determined using the colorimetric
method.
2.9. Statistical Analysis. Data are expressed as means ±
S.E.M. and were analyzed statistically by one-way ANOVA,
followed by post hoc (LSD) test. The results were considered
statistically signiﬁcant at P value < 0.05.
3. Results
3.1. Morris Water Maze Test. Cognitive impairment is
commonly observed in Parkinson patients. Therefore, we
examined the eﬀect of quercetin on spatial memory by using
the Morris water maze test and recorded escape latency
and retention time as the indices. The results were shown
in Figures 1 and 2. Figure 1 demonstrates that 6-OHDA6 Evidence-Based Complementary and Alternative Medicine
injection signiﬁcantly increased escape latency (P < 0.001
compared to control). Both L-dopa and vitamin C could
decrease escape latency throughout the observation period
(day 7: P < 0.001 and 0.01, respectively, compared to
vehicle+6-OHDA; day 14: P < 0.001 all, compared to
vehicle+6-OHDA). At the 7th day after lesion, all doses of
quercetin (100, 200, and 300mg/kg BW) used in this study
signiﬁcantly decreased the escape latency (P < 0.05, 0.01, and
0.001, resp., compared to vehicle+6-OHDA). The beneﬁcial
eﬀect of quercetin to improve learning and memory was
also observed throughout the 14-day period after lesion (P
< 0.001 all, compared to vehicle+6-OHDA).
Figure 2 shows that 6-OHDA injection signiﬁcantly
decreased retention time (P < 0.05 and 0.01 at day 7 and day
14, resp., compared to control). However, only the high dose
of quercetin signiﬁcantly increased retention time at 7 days
after lesion (P < 0.05 compared to vehicle+6-OHDA). When
the treatment was prolonged further to 14 days after lesion,
alldosesofquercetin-treatedgroupscouldenhanceretention
time (P < 0.05, 0.01, 0.01 resp., compared to vehicle+6-
OHDA) as similar as the positive modulation eﬀect of L-
dopa and vitamin C (P < 0.01 and 0.05 resp., compared to
vehicle+6-OHDA).
3.2.DensityofSurvivalNeuronintheHippocampus. Previous
information reported that the hippocampus plays a crucial
role in learning and memory. Therefore, we also determined
the eﬀect of quercetin on the neuron density in the various
subregions (CA1, CA2, CA3, and dentate gyrus) of the
hippocampus. The results are shown in Figure 3. 6-OHDA
injection signiﬁcantly produced the neurodegeneration in all
subregions of the hippocampus (P < 0.001, 0.001, 0.001,
and 0.01 for CA1, CA2, CA3, and the dentate gyrus resp.,
compared to control). L-dopa-treated group signiﬁcantly
increased the neuron density in both CA2 and the dentate
gyrus (P < 0.01 and 0.05 resp., compared to vehicle+6-
OHDA) while vitamin C-treated group showed a signiﬁcant
increase of neuron density only in CA2 (P < 0.05 compared
to vehicle+6-OHDA). Quercetin at a dose of 300mg/kg BW
signiﬁcantly increased neuron density in all subregions of
the hippocampus (P < 0.01, 0.01, 0.01, and 0.05 resp., com-
pared to vehicle+6-OHDA). The medium dose of quercetin
(200mg/kgBW) signiﬁcantly enhanced neuron density in
CA1, CA2, and CA3 (P < 0.01, 0.01 and 0.05 resp., compared
to vehicle+6-OHDA), while the low dose or quercetin at
dose of 100mg/kg BW could signiﬁcant increase the neuron
density in only CA2 (P < 0.05 compared to vehicle+6-
OHDA).
3.3. Acetylcholinesterase Activity. Based on the knowledge
that cholinergic system plays the crucial role in spatial
memory, the eﬀect of quercetin on the activity of AChE,
an indirect indicator of cholinergic function was evaluated.
It was found that the high dose of quercetin signiﬁcantly
decreasedtheAChEactivityinthehippocampalhomogenate
(P < 0.05 compared to vehicle+6-OHDA; Figure 4). How-
ever, the low and medium doses (100 and 200mg/kgBW,
resp.) of quercetin and both positive control groups (L-
dopa and vitamin C treatments) failed to produce signiﬁcant
a l t e r a t i o n so nt h i se n z y m ea c t i v i t y .
3.4. Determination of Malondialdehyde Level and Scavenging
Enzymes Activities. The right hippocampus was isolated in
order to determine MDA levels and scavenging enzyme
activities. The results are shown in Figures 5, 6, 7,a n d8.
It was found that 6-OHDA injection signiﬁcantly increased
MDA level (P < 0.01 compared to control) but decreased
the activity of GPx (P < 0.01 compared to control). Both
positive-control-treated groups failed to show a signiﬁcant
reduction of MDA levels in the hippocampus while the high
dose of quercetin used in this study signiﬁcantly decreased
MDA levels in the mentioned area (P < 0.05 compared to
vehicle+6-OHDA). In addition, both L-dopa and vitamin C
alsoincreasedtheactivitiesofSOD(P <0.01all,comparedto
vehicle+6-OHDA), GPx (P < 0.01 and 0.05 resp., compared
to vehicle+6-OHDA). However, only rats subjected to L-
dopa showed signiﬁcantly increased CAT activity (P < 0.05
compared to vehicle+6-OHDA). Interestingly, it was found
that the rats subjected to the high dose of quercetin had
signiﬁcantly enhanced SOD, CAT, and GPx activity in the
hippocampus (P < 0.01, 0.01, and 0.05 resp., compared to
vehicle+6-OHDA). The medium and low doses of quercetin-
treated groups also had signiﬁcantly increased GPx activity
in the aforementioned area (P < 0.05 all, compared to
vehicle+6-OHDA).
4. Discussion
The results of this study clearly show the cognitive enhancing
eﬀect of quercetin in this PD model. It was found that
treatment with quercetin for two weeks before and after a
6-OHDA injection can improve performance in the Morris
water maze test of the rats.
6-OHDAisoneofthemostcommonneurotoxinsusedin
experiments in order to mimic Parkinsonism in rodents. The
possible underlying mechanism of neurotoxicity induced by
6-OHDA has been reported to be related to the oxidative
stress caused by the production of hydroxyl radicals during
autoxidation [31–33] and the inhibition of complex I [34]
resulting in excessive oxidative stress and leading to neuronal
death. Previous studies demonstrated that 6-OHDA could
produce the cognitive deﬁcit in animals [35–39], and
oxidative stress has been shown to play an important role in
memory impairment [40]. Thus, 6-OHDA is suitable to be
used to mimic Parkinsonian and also cognitive impairment
in rats (see Figure 9).
It is well known that the substantia nigra is the area of
the brain that is most aﬀected in PD but other brain areas
are also aﬀected. The hippocampus is the brain area that
plays an important role in spatial memory [41, 42], thus we
determined the cognitive performance of the rats using the
Morris water maze test which is the best tool to determine
spatial learning and memory in rodents [43].
We found that quercetin signiﬁcantly improved the cog-
nitive impairment induced by 6-OHDA injection, indicatedEvidence-Based Complementary and Alternative Medicine 7
by the decrease of time spent to ﬁnd out platform (escape
latency) and the increase of retention time.
It has been reported that there was a tight correlation
between cognitive impairment in PD and cholinergic deﬁcit
[44–46]. Therefore, we also determined the activity of AChE,
an indirect indicator to evaluate the cholinergic system.
The results of our study demonstrated that quercetin in
a high dose signiﬁcantly decreased AChE activity in the
hippocampal homogenate, which indicates that there is the
increase of available acetylcholine at the synaptic terminal
resulting in the improvement of cognitive performance by
the animals.
It was found that in Parkinson patients’ brain, there is
an increase of lipid peroxidation [47, 48]a n dad e c r e a s e
in the level of free radical scavenging enzymes [49]. The
oxidative stress-induced neuronal death is the manner of
6-OHDA model. Therefore, we evaluated the density of
survival neurons in the hippocampus. The results demon-
strated that quercetin attenuated the neurodegeneration in
all subregions of the hippocampus. In addition, we also
determined the level of MDA and the activities of scavenging
enzymes. The results of the present study demonstrate that
6-OHDA injection causes a signiﬁcant increase of MDA
levelsbutcausesasigniﬁcantdecreaseofscavengingenzymes
indicating that free radicals are eﬀectively involved in the
development of cognitive impairment in PD.
It is not clear how 6-OHDA produces oxidative stress
in the hippocampus. Based on the knowledge that there
are four main pathways of dopaminergic system, one of
them is mesolimbic pathway which connects between the
ventral tegmental area and the limbic system and includes
the hippocampus. Moreover, it has been shown that the
dentategyrusofthehippocampusreceivedthedopaminergic
projection form the ventral tegmental area (A10) and the
substantia nigra (A9) [50, 51].
In the present study, we injected 6-OHDA into the
substantia nigra and because the nearby structure ventral
tegmental area contains dopaminergic neuron thus these
neurons might uptake the toxin into their cells too. There-
fore, the dopaminergic connection to the hippocampus
mightbeaﬀectedleadingtotheoxidativestressandcognitive
impairment observed in the animals. Even though we
observedtheneuroprotectiveeﬀectofquercetininthisstudy,
we could not ignore recent information showing the pro-
neurotoxic eﬀect of quercetin if there is coexposure with
methylmercury [52].
However, the results obtained from this study failed to
show a dose-dependent manner. The possible explanation
could be related to the rapid metabolism of quercetin [53].
Therefore, we observed the positive results only in the high-
dose-treated group but not in the lower two doses because
the active metabolites of quercetin might not be able to reach
to therapeutic level and produce the signiﬁcant eﬀect on the
parameters measured by this experiment.
Previous studies strongly emphasized that quercetin is
considered as a surpass free-radical scavenging antioxidant
[54–56] owing to a high number of hydroxyl groups and
an ability to donate electrons or hydrogens, and scavenge
hydroxyl groups, hydrogen peroxide, and superoxide anions
[57]. It was found that quercetin reverses the cognitive
deﬁcitinducedbychronicreserpineadministration[58].The
mechanisms behind this action could be a direct or indirect
eﬀect of quercetin to scavenge free radicals and oxidize
metabolitesorfromironorcopperchelatingandinhibitlipid
peroxidation properties [59, 60]. Quercetin was reported to
promote glutathione peroxidase [61], reverse the decrease of
antioxidant defense of glutathione peroxidase, catalase, and
superoxide dismutase induced by UVA light [62], and inhibit
the hydrogen peroxide-induced oxidative damage [63, 64].
Our results suggest that the cognitive-enhancing eﬀect
of quercetin might be due to its antioxidant eﬀect by
promotingtheactivitiesofscavengingenzymestoprotectthe
neurons from oxidative damage contributing to the survival
of neurons in the hippocampus. However, we also observed
a slight decrease in antioxidant enzymes in normal control
rats. This is possibly due to the prooxidant eﬀect of quercetin
in normal cells [65].
Notably, only quercetin in high doses signiﬁcantly
decreased AChE activity resulting in the increase of available
acetylcholine, an important neurotransmitter, which plays
the crucial role in learning and memory process. However,
the results in this study have also shown the beneﬁcial eﬀect
on memory in the lower two doses of quercetin (100 and
200mg/kgBW) but they failed to produce the signiﬁcant
suppression on AChE. We suggest that the improvement of
cognition is likely to be related with an increase of neuron
density.
5. Conclusion
It was concluded that quercetin exerts the cognitive enhanc-
ing eﬀect in this PD model via its antioxidant eﬀect
resultinginthepromotionofneuronsurvival.Consequently,
the use of quercetin as an adjuvant therapeutic agent for
the treatment of cognitive impairment in PD should be
considered.However,furtherinvestigationsarestillrequired.
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